Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC

Neoadjuvant treatment using osimertinib, with or without chemotherapy, is recommended for patients with resectable, EGFR-mutated stage II to IIIB non-small cell lung cancer (NSCLC). This guidance stems from the NeoADAURA trial findings presented by Dr. Jamie E. Chaft, highlighting improved outcomes compared to traditional chemoimmunotherapy. With significant major pathologic response rates and low adverse effects, osimertinib treatment showcased an enhanced potential for successful surgeries and continued adjuvant therapy in this patient group.